DexCom (DXCM) stock has been in focus after Investor Day communications that many fund managers say improved sentiment, ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Bell Global Equities Fund, managed by Bell Asset Management, released its May investor update. A copy of the letter can be ...

DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed ...

The FDA’s indication expansion for Dexcom’s Stelo makes it the first over the counter CGM available for children, including those with diabetes.

In a report released on July 6, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom, with a price target of $84.00. The company’s shares closed yesterday at $72.38. 55% O ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...